Skip to main content
OpenTrials

Clinical trial condition

Adenocarcinoma

Explore clinical trials studying Adenocarcinoma. Study availability and eligibility vary by location and protocol.

5,067 public trials 1,185 recruiting studies
Refine in advanced search Browse all conditions

Adenocarcinoma trial results

Active, not recruiting

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

NCT06048133

Conditions
Adenocarcinoma, Bile Duct Cancer, Bile Duct Diseases, +12 more
Locations
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center Indianapolis, Indiana, United States
  • University of Michigan Health System Ann Arbor, Michigan, United States
  • Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States
  • University of Wisconsin Madison, Wisconsin, United States
View Trial Details
Active, not recruiting

Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer

NCT01266642

Conditions
Adenocarcinoma, Breast Carcinoma In Situ, Breast Diseases, +19 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • UF Cancer Center at Orlando Health Orlando, Florida, United States
  • MD Anderson in The Woodlands Conroe, Texas, United States
  • M D Anderson Cancer Center Houston, Texas, United States
View Trial Details
Active, not recruiting

Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study

NCT04550481

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +12 more
Locations
  • Cedars Sinai Medical Center Los Angeles, California, United States
  • Mayo Clinic in Rochester Rochester, Minnesota, United States
  • Mount Sinai Hospital New York, United States
  • Duke University Medical Center Durham, North Carolina, United States
View Trial Details
Active, not recruiting

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

NCT04736706

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • The University of Alabama at Birmingham ( Site 0010) Birmingham, Alabama, United States
  • UC San Diego ( Site 0050) La Jolla, California, United States
  • Cedars Sinai Medical Center ( Site 0027) Los Angeles, California, United States
  • University of California Irvine ( Site 0029) Orange, California, United States
View all 262 locations
View Trial Details
Active, not recruiting

Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

NCT03847428

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations
  • Research Site Birmingham, Alabama, United States
  • Research Site Mobile, Alabama, United States
  • Research Site Phoenix, Arizona, United States
  • Research Site Costa Mesa, California, United States
View all 217 locations
View Trial Details
Active, not recruiting

Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer

NCT01038778

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +17 more
Locations
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
  • Roswell Park Cancer Institute Buffalo, New York, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
View Trial Details
Active, not recruiting

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

NCT03660826

Conditions
Adenocarcinoma, Adnexal Diseases, Carcinoma, +28 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
View all 761 locations
View Trial Details

Related conditions